AwardTape · Defense awards · Hemoglobin Oxygen Therapeutics LLC
Hemoglobin Oxygen Therapeutics LLC: $9.6M in DoD and DHS awards
Hemoglobin Oxygen Therapeutics LLC holds 1 DoD and DHS prime award with $9.6M obligated May 22, 2025 to Mar 16, 2026. Largest category: Health R&D at $9.6M; largest buyer: Defense Health Agency at $9.6M.
| Obligated FY2024+ | $9.6M |
|---|---|
| Awards | 1 |
| FY2024 | $0 |
| FY2025 | $8.7M |
| FY2026 to date | $820K |
| Lifetime obligated on these awards | $9.6M |
| First and latest action | May 22, 2025 · Mar 16, 2026 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Health R&D | $9.6M | 1 awards | 100% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense Health Agency | $9.6M | 1 awards | 100% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| HT942525C0035 definitive contract | $9.6M | Canine oxygen carrier manufacturing restoration and regulatory activities | Defense Health Agency | Health R&D | Mar 16, 2026 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial